MA51779A - Molécule de liaison ayant une activité neutralisante contre le coronavirus du syndrome respiratoire du moyen-orient - Google Patents

Molécule de liaison ayant une activité neutralisante contre le coronavirus du syndrome respiratoire du moyen-orient

Info

Publication number
MA51779A
MA51779A MA051779A MA51779A MA51779A MA 51779 A MA51779 A MA 51779A MA 051779 A MA051779 A MA 051779A MA 51779 A MA51779 A MA 51779A MA 51779 A MA51779 A MA 51779A
Authority
MA
Morocco
Prior art keywords
liaison
coronavirus
molecule
activity against
respiratory syndrome
Prior art date
Application number
MA051779A
Other languages
English (en)
Inventor
Yeon Jin Bae
Hee Jin Cheong
Cheol Min Kim
Woo Joo Kim
Soo Young Lee
Ji Yun Noh
Man Seong Park
Joon Young Song
Kyung Min Song
Kye Sook Yi
Original Assignee
Celltrion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltrion Inc filed Critical Celltrion Inc
Publication of MA51779A publication Critical patent/MA51779A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA051779A 2018-01-31 2018-11-30 Molécule de liaison ayant une activité neutralisante contre le coronavirus du syndrome respiratoire du moyen-orient MA51779A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20180011776 2018-01-31
KR1020180108125A KR20190093107A (ko) 2018-01-31 2018-09-11 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자
KR1020180138228A KR20190093110A (ko) 2018-01-31 2018-11-12 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자

Publications (1)

Publication Number Publication Date
MA51779A true MA51779A (fr) 2021-05-05

Family

ID=67613226

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051779A MA51779A (fr) 2018-01-31 2018-11-30 Molécule de liaison ayant une activité neutralisante contre le coronavirus du syndrome respiratoire du moyen-orient

Country Status (12)

Country Link
US (1) US20220177552A1 (fr)
EP (1) EP3747902A4 (fr)
JP (1) JP2021512599A (fr)
KR (3) KR20190093107A (fr)
CN (1) CN111727199A (fr)
AU (1) AU2018405442A1 (fr)
BR (1) BR112020015475A2 (fr)
CA (1) CA3090327A1 (fr)
EA (1) EA202091781A1 (fr)
JO (1) JOP20200183A1 (fr)
MA (1) MA51779A (fr)
TN (1) TN2020000157A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4186922A1 (fr) 2020-07-24 2023-05-31 Celltrion, Inc. Molécule de liaison ayant une activité de neutralisation contre une superfamille de coronavirus
KR20220061903A (ko) * 2020-11-06 2022-05-13 주식회사 녹십자 코로나바이러스 스파이크 단백질에 특이적인 항체 및 이의 용도
CN113009154B (zh) * 2021-02-25 2024-01-30 山东莱博生物科技有限公司 一步法新型冠状病毒中和抗体磁性微球检测试剂盒及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10421802B2 (en) * 2013-10-18 2019-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides
KR20160145813A (ko) * 2014-04-25 2016-12-20 다나-파버 캔서 인스티튜트 인크. 중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법
JO3701B1 (ar) * 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
EP3183839B1 (fr) * 2014-08-18 2020-10-21 Nokia Solutions and Networks Oy Sécurité d'activateur de service de communication de groupe
WO2016080591A1 (fr) * 2014-11-17 2016-05-26 유한회사 바이오노트 Anticorps reconnaissant la nuclécapside du coronavirus du syndrome respiratoire du moyen-orient et son utilisation
CN104447986B (zh) * 2014-12-23 2017-12-29 中国科学院微生物研究所 一种中东呼吸综合征冠状病毒中和抗体及其制备方法
EP3261665A1 (fr) * 2015-02-24 2018-01-03 The United States of America, as represented by The Secretary, Department of Health and Human Services Immunogènes du coronavirus du syndrome respiratoire du moyen-orient, anticorps et leur utilisation
KR101828794B1 (ko) * 2016-11-14 2018-02-13 (주)셀트리온 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 항체

Also Published As

Publication number Publication date
KR20190093107A (ko) 2019-08-08
CN111727199A (zh) 2020-09-29
JP2021512599A (ja) 2021-05-20
JOP20200183A1 (ar) 2022-10-30
BR112020015475A2 (pt) 2020-12-08
KR20190093110A (ko) 2019-08-08
US20220177552A1 (en) 2022-06-09
KR20190093114A (ko) 2019-08-08
EP3747902A4 (fr) 2021-12-01
TN2020000157A1 (en) 2022-04-04
EA202091781A1 (ru) 2020-10-21
EP3747902A1 (fr) 2020-12-09
AU2018405442A1 (en) 2020-08-20
CA3090327A1 (fr) 2019-08-08

Similar Documents

Publication Publication Date Title
DK3658539T3 (da) Forbindelser og sammensætninger til behandling af tilstande, som er forbundet med nlrp-aktivitet
MA40688A (fr) Anticorps humains contre la protéine de pic monoclonal du coronavirus du syndrome respiratoire du moyen-orient
DK3289080T3 (da) Genterapi til autosomalt dominante sygdomme
CL2020000173S1 (es) Masajeador.
EA201791874A1 (ru) Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
DK3513809T3 (da) Medicinsk sammensætning, som omfatter tivozanib
BR112018005754A2 (pt) benzamidas substituídas por isoxazolina e análogos como inseticidas.
MA51779A (fr) Molécule de liaison ayant une activité neutralisante contre le coronavirus du syndrome respiratoire du moyen-orient
IL280097B1 (en) Acid gas treatment
CL2019003599S1 (es) Extintor.
BR112017021527A2 (pt) dentifrícios com base em cálcio para acentuar absorção de ingredientes ativos.
DK3911354T3 (da) AVV-formidlet genterapi, der genskaber otoferlin-genet
CL2020000212S1 (es) Inhalador.
DK3788912T3 (da) Stolearrangement
ZA201800940B (en) Use of il-3, il-33, and il-12p40 for characterization of the respiratory infections by syncytial respiratory virus
CL2020000208E1 (es) Inhalador.
MA51197A (fr) Pyrazolopyrimidines ayant une activité contre le virus respiratoire syncytial (vrs)
MA51450A (fr) Orge ayant une activité enzymatique hydrolytique accrue
MA50220A (fr) Enzymes de lactase ayant une activité améliorée à basses températures
DE112016001698A5 (de) Elastischer Gelenkkörper
ES1235689Y (es) Cuna de viaje
UA41159S (uk) Піномонтажний пістолет
ES1245126Y (es) Revestimiento purificante para suelos
ES1229527Y (es) Estructura para atomizador agricola.
UA43099S (uk) Інгалятор